Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Relationship between Distal Vessel Quality and Outcomes in the Treatment of Chronic Total Occlusions

Percutaneous treatment of chronic total occlusions has increase, and has become a a more habitual therapeutic challenge. However, there is limited information on distal vessel quality and its association with outcomes and techniques. This variable appears to be excluded form CTO scores, except for the RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom). 

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

With this lack of information in mind, a multicenter registry was carried out to assess the association of distal vessel quality and CTO PCI outcomes. 

Primary end point was inhospital major adverse cardiovascular events (MACE), which included death, acute myocardial infarction (AMI), target vessel emergency revascularization, cardiac tamponade requiring pericardiocentesis or surgery, and stroke. 

Poor distal vessel quality was defined as < 2mm vessel diameter or significant diffuse atherosclerosis. A total 10,028 CTO PCI procedures between 2012 and 2022 were looked into. Patient mean age was 64, and they were mostly men. 33% of cases had poor distal vessel quality. 

Patients with poor distal vessel quality more often presented prior PCI, CABG, diabetes, hypertension, dyslipidemia, AMI, cerebrovascular disease, cardiac failure and peripheral artery disease. They also showed lower ejection fraction. 

Read also: Cerebrovascular Events in the COAPT Study.

The right coronary artery was the most treated (52.8%), while the anterior descending was less prevalent in group with poor distal vessel quality (23.6% vs. 27.2%; P < 0.001). On the other hand, the circumflex was the most frequently treated among the latter (21.5% vs. 17.9%; P < 0.001).

Lesions in this group were more complex, presented higher J-CTO and PROGRESS-CTO scores, more moderate to severe calcification, proximal cap ambiguity, long occlusions and smaller target vessel proximal diameter. These lesions required more stents. 

As regards procedure characteristics, the anterograde strategy was the most successful in both groups, with 60% success rate in the good quality group and 48% in poor quality patients. Lesions with poor distal vessel quality more often required retrograde access, but not anterograde dissection and reentry. Also, intravascular imaging was used in 41.8% of cases.

Read also: Transcatheter Mitral Valve Replacement vs. Medical Therapy.

Technical success, both procedural and general, was significantly lower among poor target vessel quality CTO PCIs (79.9% vs. 86.9%; P < 0.001 y 78.0% vs. 86.8%; P < 0.001, respectively). Primary end point showed higher inhospital MACE (2.5% vs. 1.7%; P = 0.01) and perforation incidence (6.4% vs. 3.7%; P < 0.01) in the group with poor distal vessel quality. Even though individual differences were not statistically significant, there was a tendency towards higher mortality (0.54% vs. 0.28%; P = 0.05) and tamponade (1.1% vs. 0.78%; P = 0.07) in the poor distal vessel quality group.  

Conclusions 

Poor distal vessel quality in CTO PCI is associated with more complex lesions, more use of retrograde crossing strategies, lower technical and procedural success, higher in hospital MACE and coronary perforation incidence, and higher radiation exposure. Therefore, distal vessel quality in CTO should be taken into account when planning and performing PCI. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Distal Target Vessel Quality and Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention.

Reference: Salman S. Allana, MD et al J Am Coll Cardiol Intv 2023;16:1490–1500.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...